drugset / Trial / NCT06940154
Rademikibart Add-on Treatment of an Acute COPD Exacerbation (Seabreeze STAT COPD)
RandomizedParallel-groupQuadruple-blindTreatment
Summary
This is a Phase 2, multicenter study in adult participants with an acute COPD exacerbation and type 2 inflammation
Timeline
- Start
- 2025-08-12
- Primary completion
- 2026-07-30
- Completion
- 2026-08-27
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Rademikibart | Monoclonal antibody | 600 mg | Subcutaneous |